Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Humans
Antiviral Agents
/ adverse effects
Sofosbuvir
/ adverse effects
Hepacivirus
/ genetics
Hepatitis C, Chronic
/ drug therapy
Ribavirin
/ therapeutic use
Carcinoma, Hepatocellular
/ drug therapy
Sustained Virologic Response
Liver Neoplasms
/ drug therapy
Treatment Outcome
Hepatitis C
/ drug therapy
Genotype
Drug Therapy, Combination
HCV genotype
RAS mutation
adverse effects
direct-acting antiviral
liver cirrhosis
ribavirin
sustained virological response
treatment
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
30 06 2023
30 06 2023
Historique:
received:
06
06
2023
revised:
27
06
2023
accepted:
27
06
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in DAA-experienced CHC patients remains sparse. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of SOF/VEL/VOX as a salvage treatment in DAA-experienced CHC patients. We searched five electronic databases from inception to 31 January 2023. The study outcomes were SVR12 and treatment-related adverse effects, with subgroup analysis performed based on genotype, cirrhosis, HCC, prior SOF/VEL exposure, and region. We identified and analyzed data from 24 studies (2877 DAA-experienced CHC patients); 17.2% had prior SOF/VEL exposure, 25% received ribavirin with SOF/VEL/VOX, and 42% had pre-treatment resistance-associated substitution (RAS) testing performed. Eastern Mediterranean had a higher pooled SVR12 than the America and Europe regions (
Identifiants
pubmed: 37515176
pii: v15071489
doi: 10.3390/v15071489
pmc: PMC10384139
pii:
doi:
Substances chimiques
Antiviral Agents
0
Sofosbuvir
WJ6CA3ZU8B
voxilaprevir
0570F37359
velpatasvir
KCU0C7RS7Z
Ribavirin
49717AWG6K
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415
pubmed: 35180382
Eur J Gastroenterol Hepatol. 2021 Jun 1;33(6):859-861
pubmed: 32541241
Am J Gastroenterol. 2019 Sep;114(9):1550-1552
pubmed: 31082871
J Viral Hepat. 2021 Sep;28(9):1256-1264
pubmed: 34003556
Int J Antimicrob Agents. 2020 Sep;56(3):106067
pubmed: 32599227
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
J Viral Hepat. 2019 Aug;26(8):980-990
pubmed: 31012179
World J Hepatol. 2022 Jun 27;14(6):1248-1257
pubmed: 35978662
Liver Int. 2021 Mar;41(3):456-463
pubmed: 33389788
N Engl J Med. 2017 Jun 1;376(22):2134-2146
pubmed: 28564569
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358
pubmed: 32772078
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Z Gastroenterol. 2020 Sep;58(9):841-846
pubmed: 32947629
J Hepatol. 2019 Oct;71(4):666-672
pubmed: 31203153
J Hepatol. 2023 Aug;79(2):314-320
pubmed: 37088312
J Gastrointestin Liver Dis. 2022 Dec 17;31(4):437-443
pubmed: 36535062
Rev Inst Med Trop Sao Paulo. 2022 Sep 05;64:e50
pubmed: 36074445
J Hepatol. 2019 Dec;71(6):1106-1115
pubmed: 31433303
Hepatol Int. 2023 Apr;17(2):291-302
pubmed: 36701081
J Viral Hepat. 2019 Jun;26(6):770-773
pubmed: 30663168
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):542-551
pubmed: 35248212
Clin Infect Dis. 2021 Jun 1;72(11):e799-e805
pubmed: 33677545
J Gastroenterol Hepatol. 2021 May;36(5):1300-1308
pubmed: 33217040
J Gastroenterol Hepatol. 2022 Aug;37(8):1642-1644
pubmed: 35723645
J Hepatol. 2022 Feb;76(2):302-310
pubmed: 34592366
Clin Infect Dis. 2021 Nov 2;73(9):e3288-e3295
pubmed: 32887983